Ge Long Hui·2025-06-05 18:32Group 1: Market Activity - Meituan-W recorded a net buy of HKD 5.55 million, with a trading volume of HKD 24.70 billion, reflecting a price increase of 3.0% [3] - Alibaba-W saw a net sell of HKD 0.39 million, with a trading volume of HKD 23.71 billion, and a price increase of 0.6% [3] - Tencent Holdings experienced a net sell of HKD 14.36 million, with a trading volume of HKD 17.96 billion, and a price increase of 1.4% [3] - Xinda Biologics had a significant price increase of 14.1%, with a net buy of HKD 2.97 million and a trading volume of HKD 22.00 billion [3] Group 2: Fund Flows - Southbound funds have continuously net bought Meituan for 13 days, totaling HKD 144.1059 million, and have net bought Xinda Biologics for 4 days, totaling HKD 22.5265 million [4] - Southbound funds have net bought Alibaba for 3 days, totaling HKD 16.494 million, while they have net sold Tencent for 4 days, totaling HKD 30.6792 million [4] Group 3: Company Developments - Xinda Biologics reported positive clinical trial results for its first-in-class PD-1/IL-2α-bias dual-specific antibody IBI363 for advanced non-small cell lung cancer at the 2025 ASCO annual meeting [6] - BYD plans to launch a low-cost micro electric vehicle in Japan next year, targeting the USD 18 billion microcar market, and reported a 15.3% year-on-year increase in May's new energy vehicle sales [7] - Xiaomi Group faced a net sell of HKD 13.75 million, with a focus on its upcoming product launch and a gradual reduction in losses from its automotive business, expecting profitability in the third to fourth quarter of this year [7]